- Design
- Systematic review of preclinical and clinical studies
- Population
- 21 studies; 18 clinical studies including 8,910 patients with RA on TNF inhibitors
- Primary outcome
- Effect of rheumatoid factor level on TNF inhibitor drug levels and outcomes
- Effect
- Outcomes similar or slightly better in high-RF patients on Fc-free TNF inhibitors
A systematic review of 21 studies (Annals of the Rheumatic Diseases, 5 October 2026), including 18 clinical studies with 8,910 patients, examined whether high rheumatoid factor levels reduce the effect of TNF inhibitors in rheumatoid arthritis. Rheumatoid factor binds the Fc portion of IgG and can bind Fc-containing biologics, forming immune complexes that are cleared, potentially lowering drug levels.
In patients with high rheumatoid factor, disease activity outcomes and Boolean remission were similar or slightly better with Fc-free TNF inhibitors than in those with low rheumatoid factor. The authors conclude that Fc-free agents may offer some advantage in this group.
The evidence is indirect and largely observational, and the review does not compare drugs head to head within high-RF patients. It is a plausible consideration when choosing among TNF inhibitors, not a reason to switch a patient who is responding.
- Record rheumatoid factor titre, not just positivity, before choosing a biologic.
- Consider an Fc-free TNF inhibitor when a high-RF patient starts TNF inhibition, where available and affordable.
- Do not switch a patient who is responding well on an Fc-containing agent on this basis.
- Check drug levels and antidrug antibodies, where available, when a TNF inhibitor fails.
Why it matters
It offers a mechanistic reason why some seropositive patients do worse on certain TNF inhibitors.
Don't overread it
The review compared high- with low-RF patients rather than Fc-free with Fc-containing agents directly, so it cannot prove one class is better.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for rheumatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free